FDA Sends an Interim Peptide Compounding Policy to OMB: What It Would and Would Not Do

A regulatory shift that could reshape how Americans buy peptides moved one step forward in October 2026. The Department of Health and Human Services and the FDA submitted a draft Interim Access Policy for Compounding Using Certain Peptides to the Office of Management and Budget on October 14, 2026, according to a posting on the government's regulatory review site and reporting by the Associated Press. The document is under OMB review, its text has not been released, and it has not taken effect. What reporting and legal analysts describe is a policy that would use enforcement discretion, not new law, to open a limited lane for compounding peptides such as BPC-157 through state-licensed pharmacies.

What was submitted, and to whom

OMB, through its Office of Information and Regulatory Affairs, reviews significant regulatory actions before an agency issues them. The appearance of the Interim Access Policy for Compounding Using Certain Peptides on the pending-review list signals that the FDA has a near-final document in hand, not that a rule is in force. The policy's conditions, including which peptides it covers and any limits by route of administration, are not public while the review is pending.

Enforcement discretion, not approval

Legal analysts expect the policy to rely on enforcement discretion: a decision by the FDA not to pursue certain compounding of named peptides by state-licensed 503A pharmacies, rather than a formal authorization. Reporting indicates the intent is to assure those pharmacies they will not be targeted for preparing peptides such as BPC-157. Enforcement discretion does not approve any product, does not change the underlying statute, and does not bind state pharmacy or medical boards. Because it is a policy choice rather than a rule, the agency could narrow or withdraw it without going through rulemaking.

The expected scope is narrow in important ways. Reporting and legal summaries indicate it would apply to 503A pharmacies, which prepare patient-specific prescriptions, and not to 503B outsourcing facilities that compound in larger batches, nor to research-use-only or dietary-supplement channels.

What it would not do: the bulks list and rulemaking

An interim access policy is distinct from adding a substance to the 503A Bulks List, the FDA's roster of bulk drug substances that 503A pharmacies may use in compounding without an FDA-approved starting product. Formally listing a peptide requires notice-and-comment rulemaking, a process that can run for years and include multiple comment rounds. The FDA has not issued a proposed or final rule granting peptide access, and whether the administration still intends to complete that longer process is not clear from the public record.

How this connects to the July 2026 advisory vote

The policy follows the July 23-24, 2026 meeting of the FDA's Pharmacy Compounding Advisory Committee (PCAC), which reviewed seven peptides for the 503A list. The committee recommended adding six: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, and voted against emideltide (DSIP). Those recommendations are advisory only. Notably, the FDA's own review scientists had recommended against adding any of the seven, citing gaps in safety characterization and clinical evidence rather than proof of harm. An interim access policy issued now would give pharmacies a near-term pathway while the slower listing question remains unsettled.

For the fuller background on that meeting and the individual peptides, see our coverage of how the July PCAC vote turned out and our explainer on the 503A Bulks List.

Why the administration is moving

HHS Secretary Robert F. Kennedy Jr. has been the policy's most visible advocate. He has argued that compounding pharmacies should be able to supply peptides because patients are otherwise turning to a gray market of products made overseas with no oversight, and he directed the FDA to reconsider a short list of substances promoted heavily by wellness influencers. The peptides at the center of the debate, including BPC-157, are marketed for goals such as muscle building, injury recovery and anti-aging, none of which is an FDA-approved use.

What it means for telehealth and patients

Peptides reach most consumers through telehealth and wellness clinics, so a policy that eases supply would land directly on that channel. Telehealth companies including Hims & Hers and Noom have said they would offer peptides if the government loosens access, and analysts have put the potential market at $2 billion to $3 billion. If the policy issues as described, the practical change for patients would be a clearer legal footing for obtaining certain peptides by prescription through a licensed 503A pharmacy, rather than from research-chemical vendors that sell vials labeled not for human use.

Open questions and safety context

Several things remain unresolved. The policy has not issued, and its exact terms, covered peptides and any route-of-administration limits are unknown until it is published. The legal footing is also contested: pharmaceutical trade groups argued in PCAC comments that the FDA cannot lawfully authorize compounding through an interim policy while rulemaking is pending, which raises the prospect of a court challenge. The FDA has previously flagged peptides, including BPC-157, for compounding risks such as contamination, allergic reactions and effects on tumor growth, and it has noted that much of the available data comes from animal studies rather than human trials.

What to watch next

This is general information, not medical or legal advice. A few concrete markers will show where this is heading:

• Publication of the policy after OMB review, which is the first time its actual conditions and list of covered peptides will be knowable.
• Any FDA move toward formal rulemaking to add peptides to the 503A Bulks List, the step that would make access durable rather than discretionary.
• The second PCAC meeting, expected to take up additional peptides, and any litigation from trade groups contesting the interim approach.
• For anyone considering peptides, sourcing through a licensed clinician and a verified compounding pharmacy that can provide a certificate of analysis, rather than through unregulated vendors, regardless of how the policy lands.